Background: Primary progressive multiple sclerosis (PPMS) carries the worst prognosis of the multiple sclerosis (MS) subtypes and is currently untreatable. A previous analysis of the British Columbia MS database challenged the view that disability progression is rapid in PPMS, but identified few predictors of disease progression. Here, we extend previous analyses in an updated PPMS retrospective cohort study of prevalent cases.Methods: We used Kaplan-Meier survival analyses and Cox regression models to investigate the influence of gender, age at onset, and onset symptoms on time to and age at Expanded Disability Status Scale (EDSS) 6.0 in patients with PPMS.Results: Of 5,779 patients with definite MS, 552 (10%) had PPMS. Median time to EDSS...
Rates of progression vary widely in primary progressive multiple sclerosis. This multicenter study a...
BACKGROUND AND PURPOSE: Treatments for progressive-onset multiple sclerosis (MS) are lacking. To imp...
The clinical features of relapses and progression largely define multiple sclerosis phenotypes. A re...
Background: Primary progressive multiple sclerosis (PPMS) carries the worst prognosis of the multipl...
BACKGROUND: A minority of patients with multiple sclerosis (MS) have primary progressive disease (PP...
We report a natural history study of 216 patients with primary progressive (PP)- multiple sclerosis ...
Background: Several natural history studies on primary progressive multiple sclerosis (PPMS) patient...
Background: Several natural history studies on primary progressive multiple sclerosis (PPMS) patient...
Background The onset of secondary progression is a pivotal event in the course of relapsing-remittin...
<div><p>Background</p><p>New agents with neuroprotective or neuroregenerative potential might be exp...
Background: The clinical trial design for primary progressive multiple sclerosis (PPMS) requires und...
OBJECTIVES: To assess factors affecting the rate of conversion to secondary progressive (SP) multipl...
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating and neurodegenerative disease of t...
BACKGROUND: The course and prognosis of childhood-onset multiple sclerosis have not been well descri...
Rates of progression vary widely in primary progressive multiple sclerosis. This multicenter study a...
BACKGROUND AND PURPOSE: Treatments for progressive-onset multiple sclerosis (MS) are lacking. To imp...
The clinical features of relapses and progression largely define multiple sclerosis phenotypes. A re...
Background: Primary progressive multiple sclerosis (PPMS) carries the worst prognosis of the multipl...
BACKGROUND: A minority of patients with multiple sclerosis (MS) have primary progressive disease (PP...
We report a natural history study of 216 patients with primary progressive (PP)- multiple sclerosis ...
Background: Several natural history studies on primary progressive multiple sclerosis (PPMS) patient...
Background: Several natural history studies on primary progressive multiple sclerosis (PPMS) patient...
Background The onset of secondary progression is a pivotal event in the course of relapsing-remittin...
<div><p>Background</p><p>New agents with neuroprotective or neuroregenerative potential might be exp...
Background: The clinical trial design for primary progressive multiple sclerosis (PPMS) requires und...
OBJECTIVES: To assess factors affecting the rate of conversion to secondary progressive (SP) multipl...
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating and neurodegenerative disease of t...
BACKGROUND: The course and prognosis of childhood-onset multiple sclerosis have not been well descri...
Rates of progression vary widely in primary progressive multiple sclerosis. This multicenter study a...
BACKGROUND AND PURPOSE: Treatments for progressive-onset multiple sclerosis (MS) are lacking. To imp...
The clinical features of relapses and progression largely define multiple sclerosis phenotypes. A re...